Zobrazeno 71 - 80
of 158
pro vyhledávání: '"Pavlos Papakostas"'
Autor:
Dimosthenis Miliaras, Maria Sotiropoulou, Dimitrios Bafaloukos, Ioannis Efstratiou, Pavlos Papakostas, Georgia Karayannopoulou, Georgia Gourgioti, Anna Batistatou, Anna Koumarianou, Konstantine T. Kalogeras, George Pentheroudakis, Gerasimos Aravantinos, Evangelia Razis, Eleni Galani, Mattheos Bobos, Dimitrios Pectasides, George Fountzilas, Kalliopi Petraki, Haralabos P. Kalofonos
Publikováno v:
Cancer chemotherapy and pharmacology. 75(6)
The urokinase plasminogen activator (uPA) and the plasminogen activator inhibitor 1 (PAI-1) are associated with an aggressive course in breast cancer and are used to determine whether chemotherapy is needed in node-negative patients. The objective of
Autor:
Dimitrios Pectasides, Gerasimos Aravantinos, Pavlos Papakostas, F. Matsiakou, Helena Linardou, Haralambos P. Kalofonos, George Fountzilas, Dimitrios Bafaloukos, Giannis Mountzios, Zoi Alexopoulou, Ioannis Varthalitis, Konstantinos Laschos, Eleni Timotheadou, Angelos Koutras, Eleni Galani, Christos Christodoulou
Publikováno v:
Molecular and clinical oncology. 4(2)
Prophylactic erythropoiesis-stimulating agent (ESA) administration for chemotherapy-induced anemia (CIA) is not supported by current guidelines. Long-term follow-up of patients WHO had been treated with ESA for CIA in the past may provide useful info
Autor:
Eleni Timotheadou, Ioannis Efstratiou, Christos Christodoulou, Theofanis Economopoulos, George Fountzilas, Pavlos Papakostas, Dimitrios G. Pectasides, Dimosthenis Skarlos, Helen Gogas, Christos Papadimitriou
Publikováno v:
Medical Oncology. 23:479-488
Currently, randomized phase III trials have demonstrated that docetaxel is an effective strategy in the adjuvant treatment of breast cancer. However, previous attempts to incorporate docetaxel with an anthracycline in a dose-dense regimen have been u
Autor:
D. Tsavdaridis, Papadimitriou Ca, P. Makrantonakis, A. Polychronis, Pavlos Papakostas, C. Christodoulou, E. Razis, Helen Gogas, D.V. Skarlos, A. M. Dimopoulos, P. Kosmidis, Eleni Timotheadou, H. P. Kalofonos, Evangelos Briasoulis, Dimitris Bafaloukos, Urania Dafni, George Fountzilas, Christos Markopoulos, Dimitrios Pectasides, Vassiliki Siafaka, Gerassimos Aravantinos
Publikováno v:
Annals of Oncology. 16:1762-1771
Purpose: The aim of this study was to explore the effect of dose-dense sequential chemotherapy with or without paclitaxel primarily on disease-free survival (DFS) and secondarily on overall survival (OS) in patients with high-risk operable breast can
Autor:
Haralambos P. Kalofonos, George Fountzilas, George Basdanis, Pavlos Papakostas, Gerasimos Aravantinos, D. Tsavdaridis, Eleni Timotheadou, Dimitrios Bafaloukos
Publikováno v:
Tumori Journal. 91:309-313
Background The management of patients with fluoropyrimidine-resistant advanced colorectal cancer remains investigational. Irinotecan and oxaliplatin have proved effective in first-line treatment in combination with 5-fluorouracil. Study design From F
Autor:
Helena Linardou, George Fountzilas, Helen Gogas, Christos Papadimitriou, Gerassimos Aravantinos, A. Dimopoulos, Dimitris Bafaloukos, C. Kalofonos, P. Kosmidis, D.V. Skarlos, Pavlos Papakostas
Publikováno v:
British Journal of Cancer
Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated li
Autor:
Evangelia Razis, Pavlos Papakostas, Christos Christodoulou, Haralambos P. Kalofonos, George Fountzilas, Maria Karina, Helen Gogas, Gerassimos Aravantinos, Dimosthenis Skarlos, Anna Kalogera-Fountzila, D. Tsavdaridis
Publikováno v:
Cancer Investigation. 22:655-662
Advanced breast cancer (ABC) is an incurable disease. Standard first-line treatment for patients with HER-2/neu overexpressing tumors includes the combination of the humanized monoclonal antibody trastuzumab with chemotherapy, mainly paclitaxel. This
Autor:
H. P. Kalofonos, George Fountzilas, George Kouvatseas, T. Economopulos, Dimitris Bafaloukos, Eleni Timotheadou, D.V. Skarlos, Aristotle Bamias, M. Stavropoulos, Pavlos Papakostas, Jim Janinis
Publikováno v:
Cancer Investigation. 21:855-862
Standard chemotherapy in advanced colorectal carcinoma (CRC) has not yet been established. The present study was conducted to assess the efficacy and toxicity profile of CPT-11, leucovorin (LV), and bolus 5-fluorouracil (5-FU) in a weekly schedule. F
Autor:
Christos Christodoulou, George C. Zografos, Flora Zagouri, George Fountzilas, Sofia Chrisafi, Charisios Karanikiotis, George Pentheroudakis, Georgios Lazaridis, Triantafyllia Koletsa, Maria Sotiropoulou, P. Skarlos, Vassiliki Kotoula, Gerasimos Aravantinos, Pavlos Papakostas, Angelos Koutras, Mattheos Bobos, Christos Valavanis, Helen Trihia, Theofani Gavressea, Niki Arnogiannaki, Paris Kosmidis, George Kouvatseas, Dimitrios Bafaloukos, Christos Papadimitriou
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0180489 (2017)
PLoS ONE
PLoS ONE
Background-Aim To evaluate the prognostic role of elaborate molecular clusters encompassing cyclin D1, cyclin E1, p21, p27 and p53 in the context of various breast cancer subtypes. Methods Cyclin E1, cyclin D1, p53, p21 and p27 were evaluated with im
Autor:
Paraskevi Apostolou, Vassiliki Kotoula, George Pentheroudakis, Florentia Fostira, Ioannis Tikas, Kyriaki Papadopoulou, Sotiris Lakis, Drakoulis Yannoukakos, Flora Zagouri Zagouri, Irene Konstantopoulou, Kyriaki Manoussou, Helen Gogas, Georgios Lazaridis, Pavlos Papakostas, George Fountzilas, Dimitrios Pectasides, Christos Christodoulou, Eleftheria Tsolaki, Ioannis S. Vlachos
Publikováno v:
Cancer Research. 77:1755-1755
Background - aim: Germline mutation carriers in BRCA1 and related genes frequently develop triple-negative breast carcinomas (TNBC) that presumably preserve the inherited mutation. Herein, we examined the clinicopathologic features and prognostic imp